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The mother-to-child transmission (MTCT) rate for HIV-1 is 
15 - 40% in the absence of intervention, with most of the transmission 
occurring late in pregnancy or during labour and delivery.1,2 Treating 
HIV-infected pregnant women with combination regimens of potent 
antiretrovirals can reduce the rate of transmission to 1%.3 In 
resource-poor areas where antiretrovirals are not readily available, 
less intensive regimens, although less effective, still significantly 
reduce transmission.4 
Nevirapine (NVP) is a non-nucleoside reverse transcriptase 
inhibitor that has a potent antiviral effect (inhibitory concentration 
(IC)50 of 10 ng/ml), rapid oral absorption, good bio-availability and 
a long half-life after an initial dose (46 hours following a single 200 
mg tablet in adults), and crosses the placenta.5-8 Administering a 
single dose (sd) to the mother during labour and to the infant after 
birth reduces HIV transmission by around 40%.9,10 In term infants, 
this regimen maintained infant plasma NVP concentrations above 
100 ng/ml (10 times the in vitro IC50) throughout the first week of 
life.11,12 While approximately 18% of births in lower income settings 
are premature, there are no data describing NVP pharmacokinetics 
in premature infants.12 
Our aim was to describe NVP decay pharmacokinetics in two 
groups of premature infants: those whose mothers either received or 
did not receive NVP during labour. 
Material and methods
Site and population
The study was conducted in the Neonatology Department at 
Tygerberg Children’s Hospital from February 2005 to April 2009. 
Premature infants whose mothers were admitted during labour were 
eligible. Infant growth was classified as small (SGA), appropriate 
(AGA) or large for gestational age (LGA) using the Fenton chart.13 
All infants were fed with either formula milk or pasteurised expressed 
breastmilk. 
Inclusion criteria. Infants born to HIV-infected women before 37 
weeks’ gestation were eligible. The new Ballard score14 was primarily 
used to determine gestational age, and when it was not available, data 
from abdominal ultrasound scans or the date of the last menstrual 
Nevirapine plasma concentrations in premature infants 
exposed to single-dose nevirapine for prevention of mother-to-
child transmission of HIV-1
Pierre Mugabo, Ilse Els, Johan Smith, Helena Rabie, Peter Smith, Mark Mirochnick, Wilhelm Steyn,  
David Hall, Richard Madsen, Mark F Cotton
Background. No pharmacokinetic data exist for premature infants 
receiving single-dose nevirapine (sd NVP) for prevention of 
mother-to-child transmission (MTCT) of HIV.
Aim. To describe NVP decay pharmacokinetics in two groups of 
premature infants – those whose mothers either received or did not 
receive NVP during labour. 
Methods. Infants less than 37 weeks’ gestation were prospectively 
enrolled. Mothers received sd NVP during labour if time allowed. 
Infants received sd NVP and zidovudine. Blood was collected on 
specified days after birth and NVP concentrations were determined 
by liquid chromatography-mass spectrometry. 
Results. Data were obtained from 81 infants, 58 born to mothers 
who received sd NVP during labour (group I) and 23 to mothers 
who did not receive NVP (group II). Of the infants 29.6% 
were small for gestational age (SGA). Median (range) maximum 
concentration (Cmax), time to reach maximum concentration (Tmax), 
area under the plasma concentration-time curve (AUC) and half-
life (T½) were 1 438 (350 - 3 832) ng/ml, 25h50 (9h40 - 83h45), 
174 134 (22 308 - 546 408) ng×h/ml and 59.0 (15.4 - 532.6) hours 
for group I and 1 535 (635 - 4 218) ng/ml, 17h35 (7h40 - 29h), 
168 576 (20 268 - 476 712) ng×h/ml and 69.0 (22.12 - 172.3) hours 
for group II. For group II, the median (range) volume of distribution 
(Vd) and body clearance (Cl) were 1 702.6 (623.7 - 6 189.8) ml and 
34.9 (6.2 - 163.8) ml/h. The AUC was higher (p=0.006) and Cl 
lower (p<0.0001) in SGA infants. Plasma concentrations exceeding 
100 ng/ml were achieved over 8 days in 78% infants in group I and 
70.0% in group II. The MTCT rate was 4.8%. 
Conclusion. Women in preterm labour often deliver with little 
advance warning. Our study suggests that NVP dosing of preterm 
infants as soon as possible after birth without maternal intrapartum 
dosing may be as effective as combined maternal and infant dosing. 
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period were used. Maternal HIV infection status was determined 
according to South African Department of Health programme 
guidelines, which are based on guidance from the World Health 
Organization.15 HIV-1 antibodies were detected by a rapid test and 
positive results were confirmed on a second assay from a different 
manufacturer. Informed consent was obtained from the women 
enrolled and, when available, from the fathers. 
Exclusion criteria. Infants were excluded if their mothers were on 
long-term NVP or other antiretrovirals, or receiving any drug known 
to interfere with NVP absorption, metabolism and distribution; on 
request by the mother; or if the infant’s haematocrit was below 30%. If 
the haematocrit fell below 24% during the study, blood sampling was 
deferred until the haematocrit was higher than 24%.
Procedures 
Mothers received 200 mg NVP during labour if time allowed. All babies 
received sd NVP as soon as possible after birth. The infant NVP dose 
was 6 mg if birth weight (BW) was above 2 000 g and 2 mg/kg if it was 
below 2 000 g. Infants also received zidovudine (AZT) for 7 days, 12 mg 
twice daily if the BW was above 2 000 g and 4 mg/kg twice daily if it was 
below 2 000 g. Infant blood samples (0.2 ml) were collected on days 1, 
2, 4, 6, 8, 14 and 21 after birth. After sampling, blood was immediately 
centrifuged and the plasma was separated from the centrifugate and 
stored in a -80ºC deep freeze until the assays were performed.
Plasma concentrations of NVP were determined by liquid 
chromatography-mass spectrometry using a Waters Alliance 2690 
HPLC coupled to a Waters/Micromass ZMD single quadrapole 
mass spectrometer.16 The mobile phase consisted of 50% acetonitrile 
in 4 mM ammonium acetate, 0.1% trifluoroacetic acid. A 20×2.1 
mm Hypersil Gold C18 column (Thermo) was used at a flow rate 
of 0.3 ml/min. Neostigmine served as internal standard. Detection 
in positive ionisation mode of nevirapine was at 276.2 (m/z) 
and neostigmine at 223.2 (m/z). To precipitate protein, 50 µl of 
acetonitrile containing 1 µg/ml internal standard was added to 20 µl 
of each sample or control. Samples were vortexed for 30 seconds, and 
centrifuged for 5 minutes at 750 g. After this 2 µl of the supernatant 
was injected onto the column. The standard curve was linear to 0.1 
µg/ml. The lower limit of quantification (LLQ) was set at 100 ng/ml. 
Quality control samples of 0.8, 3 and 9 µg/ml were included with each 
run. Inter- and intra-day percentage coefficients of variation were less 
than 10% for all controls. An HIV-DNA-PCR test was done 28 days 
after birth. 
Determination of pharmacokinetic 
parameters 
After determining NVP plasma concentrations, the plasma 
concentration-time profile for each patient was plotted using GraphPad 
Prism 4 (GraphPad Software Inc., USA). NVP pharmacokinetic 
parameters were calculated using a non-compartmental analysis. 
The maximum concentration (Cmax) and time to reach the maximum 
concentration (Tmax) were obtained directly from the plasma 
concentration-time profile. The area under the plasma concentration-
time curve from zero to 21 days (AUC0-504) was calculated by the 
trapezoidal method. The AUC from zero to infinity (AUC0-∞) was 
calculated using the following formula: AUC0-504 + Cplast/ Ke, where 
Cplast is the last measurable plasma concentration. The following 
formula was used to determine the volume of distribution: Vd = dose/
(AUC0-∞ × Ke). The total body clearance (Cltot) was calculated using the 
following formula: Cltot = dose/AUC0-∞. The elimination rate constant 
(Ke) was calculated as the slope of terminal log-linear phase of the 
plasma concentration-time profile multiplied by -2.303. The half-life 
(T½) was calculated using the formula: T½ = 0.639/Ke.
Statistical analysis 
Patient data were organised and coded onto data collection forms 
and captured into Microsoft Excel spreadsheets. NVP concentrations 
and pharmacokinetic parameters were analysed using descriptive 
statistics. The proportion of infants with NVP plasma levels >100 ng/
ml on day 8 in groups 1 and 2 were compared using the chi-square 
test with the null hypothesis that the proportions for the two groups 
were equal. The statistical software used was SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Ethical considerations
The study was approved the ethics committees of the universities 
of the Western Cape (Reference Nb 04/7/10) and Stellenbosch 
(Reference Nb 04/10/183).
Results
Of 100 mothers, 68 received NVP during labour. Of their infants, 
2 were withdrawn before enough blood samples could be collected, 
1 died before the study was completed, and the volume of blood 
collected was insufficient for 7. Of the 32 infants whose mothers did 
not receive NVP, 2 were withdrawn, 1 died, and the volume of blood 
collected was insufficient for 6. Gestational age was determined 
with the new Ballard score in 59 cases (72.8%) and antenatal 
ultrasonography in 19 (23.5%).
Table I sets out the demographic data for the 81 evaluable infants. 
The median gestational age was 34 weeks (range 28 - 37 weeks) and 
the median birth weight 2 052 g (range 950 - 3 400 g) for group I and 
36 (28 - 37) weeks and 2 100 (1 028 - 3 460) g for group II. Twenty-
four (29.6%) of the infants were SGA. Sixty-three received formula 
milk and 18 pasteurised expressed breastmilk. 
NVP concentrations over time 
NVP plasma concentrations are presented in Table II and as box plots 
in Fig. 1. In the box plots the mean is denoted by +. The lower, middle 
and upper edges of the box represent the first quartile, the median 
and the third quartile, respectively. Extreme values are denoted by 
*. At 8 days after birth, 78% of infants whose mothers had received 
NVP had a NVP plasma concentration above 100 ng/ml compared 
with 70% of infants whose mothers had not received NVP (p=0.49). 
Nevirapine pharmacokinetics 
The median (range) Cmax, Tmax, AUC and T½ were 1 438.00 (350 - 
3 832) ng/ml, 25h50 (9h40 - 83h45), 174 134 (22 308 - 546 408) ng×h/
Table I. Demographics of the infants receiving NVP
Group I Group II
No. of infants 58 23
Male (N (%)) 29 (50) 11 (47.8)
Female (N (%)) 29 (50) 12 (52.2)
SGA (N (%)) 16 (27.59) 8 (34.78)
AGA (N (%)) 42 (72.41) 15 (65.22)
Time between maternal NVP 
and delivery (h) (median 
(range)) 4.33 (0.10 - 66.55) NA
Infant age at time of NVP dose 
(h) (median (range)) 0.96 (0.08 - 8.08) 0.76 (0.02 - 11.00)
NVP = nevirapine; SGA = small for gestational age.
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ml and 59.00 (15.40 - 532.60) hours, respectively, for group I and 
1 535 (635 - 4 218) ng/ml, 17h35 (7h40 - 29h), 168 576 (20  268 - 
476 712) ng×h/ml and 69.00 (22.12 - 172.26) hours for group II. The 
median (range) Vd and Cl were 1 702.56 (623.74 - 6 189.77) ml and 
34.91 (6.20 - 163.79) ml/h in group II (they could not be calculated 
in group I). The AUC was significantly higher and Cl significantly 
lower in SGA than AGA infants (Wilcoxon rank sum test p=0.006 
and p<0.0001, respectively). 
MTCT rate 
Four infants (3 from group I and 1 from group II) were infected 
(transmission rate 4.8%) (95% confidence interval 1.3 - 11.9%).
Discussion
This study presents the first pharmacokinetic data for NVP in 
premature infants, a group comprising nearly 20% of deliveries in 
South Africa. The NVP concentration on day 8 exceeded our target 
of 100 ng/ml in 78% of infants whose mothers had received sd NVP 
and 70% of infants whose mothers had not received it. In previous 
studies of full-term infants, all had NVP concentrations over 100 ng/
ml at 7 days of life if both mother and infant received sd NVP.11,13,17,18 
In our study, NVP exposure was not appreciably greater in 
infants whose mothers received intrapartum NVP compared with 
those who did not. Our median age at infant NVP dosing was less 
than 1 hour, compared with 3 - 5 hours in previous studies of the 
pharmacokinetics of single-dose NVP in term infants.11,12 Women 
in preterm labour often deliver with little advance warning, and 
our study suggests that NVP dosing of preterm infants as soon as 
possible after birth without maternal intrapartum dosing may be as 
effective as combined maternal and infant dosing. Avoiding maternal 
intrapartum NVP dosing eliminates the risk of maternal NVP 
exposure and subsequent maternal NVP resistance.19-21 
The median NVP elimination T½ in the preterm infants in our 
study was prolonged compared with that of 48.5 hours seen after 
initial doses in adults, but was not markedly different from the 64.5 
hours previously observed in term infants.16 The primary elimination 
pathway for nevirapine is oxidative metabolism by cytochrome 
P-450 enzymes of the CYP3A family, although CYP2B6 enzymes 
contribute as well.11 The major CYP3A isoform in adults is CYP 3A4, 
while fetuses express predominantly CYP3A7. After birth, CYP3A4 
activity increases and CYP3A7 decreases over the first weeks and 
months of life.22 Clearance of midazolam, a known substrate for 
CYP3A metabolism, is reduced in newborns compared with older 
children and adults but not in premature neonates compared with 
term neonates.23,24 The lack of further prolongation of NVP and 
midazolam elimination in preterm infants compared with term 
infants is probably due to CYP3A7 activity. Our data suggest that 
the 2 mg/kg dose recommended for use in term infants is also 
appropriate for use in premature infants.9  
Our study was the first to look at NVP elimination in both 
SGA and AGA preterm infants. The NVP AUC was significantly 
higher and Cl significantly lower in the SGA infants. We postulate 
that placental insufficiency could impair the levels of activity and 
maturation of CYP enzyme systems.
Conclusion
Our data support an NVP dosage of 2 mg/kg for infants born before 
37 weeks’ gestation. In term infants whose mothers do not receive 
intrapartum NVP, we recommend giving two doses of NVP, one 
immediately after birth and a second 48 - 72 hours later. Our data 
suggest that this may not be necessary in premature infants. 
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Fig. 1.   Nevirapine concentration versus time. 
Group II
Group I
Days
Days
1 2 4 14 2186
1 2 4 14 2186
lo
g1
0  
co
cn
c.
0
1
2
3
4
0
1
2
3
4
lo
g1
0  
co
cn
c.
Table II. Summary of nevirapine plasma concentrations
Day
Group 1 2 4 6 8 14 21
I N 58 54 52 42 48 23 6
Median
(range) (ng/ml)
1 438 
(350 - 3 832)
1 091
(196 - 3 055)
686
(51 - 2 658)
351
(2 - 989)
208 
(48 - 756)
142
(5 - 681)
19
(6 - 184)
N  (%) <100 ng/ml 0 (0) 0 (0) 2 (4) 3 (7) 6 (12) 9 (39) 5 (83)
II N 23 19 21 18 18 8 2
Median
(range) (ng/ml)
1 535 
(635 - 4 218)
1 176
(308 - 3 757)
625 
(10 - 2 337)
293 
(93 - 931)
136
(67 - 717)
69 
(42 - 237)
57
(2 - 111)
N  (%) <100 ng/ml 0 (0) 0 (0) 1 (5) 1 (6) 4 (22) 5 (63) 1 (50)
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 Natures pipe puffing
      Pristine plumes of dense white mist;
      Procrastinating.
 
      Gentle white blossom
      Innocent in early sp ing:
      Does not know the sun.
 
Haiku: Peter Folb 
SAMJ 100 yea s ago
SAMJ 100 years ago
